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Neuropsychiatric disorders are becoming a majorsocioeconomicburden to modern society. In recent years, a dramatic expansion
of tools has facilitated the study of the molecular basis of neuropsychiatric disorders. Molecular imaging has enabled the
noninvasive characterization and quantiﬁcation of biological processes at the cellular, tissue, and organism levels in intact living
subjects. This technology has revolutionized the practice of medicine and has become critical to quality health care. New advances
inresearch onmolecularimagingholdpromiseforpersonalizedmedicine in neuropsychiatricdisorders,withadjusted therapeutic
doses, predictable responses, reduced adverse drug reactions, early diagnosis, and personal health planning. In this paper, we
discuss the development of radiotracers for imaging dopaminergic, serotonergic, and noradrenergic systems and β-amyloid
plaques. Wewill underline the role of molecularimagingtechnologies in various neuropsychiatric disorders, describe their unique
strengths and limitations, and suggest future directions in the diagnosis and management of neuropsychiatric disorders.
1.Introduction
Modern neuroimaging oﬀers tremendous opportunities for
gaining insights into the molecular basis of neuropsychiatric
disorders. Molecular imaging shows how speciﬁc tissues
are functioning. This contrasts with conventional diagnostic
imaging procedures, which simply provide anatomical or
structural pictures of organs and tissues. Several techniques
including functional magnetic resonance imaging (fMRI)
and nuclear medicine imaging can measure regional changes
in cerebral activity; however, nuclear medicine imaging is
the only tool for direct measurements of neurotransmitter
levels and the distribution, density, and activity of receptors
or transporters. In contrast to fMRI, nuclear medicine
imaging involves the administration of radioactively labeled
tracers, which decay over time by emitting gamma rays
that can be detected by a positron emission tomography
(PET) or single photon emission computed tomography
(SPECT) scanner. The radioisotopes used in PET can reach
a more stable conﬁguration by the emission of positrons,
which travel a short distance and collide with electrons. The
annihilation of positron and electron produces 2 gamma
rays, 511keV each, which are emitted in opposite directions.
In PET, annihilation coincidence detection is used in lieu of
absorptive collimation to determine the directionality of the
detected photons; this partiallye x p l a i n st h eg r e a t e rs p a t i a l
resolution and sensitivity of PET. However, compared with
SPECT, PET is more expensive and less readily available.
The most commonly used radioisotopes for labeling PET
radiopharmaceuticals are 11Ca n d18F. 11C has a short half-
life of approximately 20min, which allows multiple studies
in the same day. In contrast, 18F has a half-life of nearly
2h, which allows shipment of tracers over considerable
distances to PET centersthat donot have a cyclotron.SPECT
radiotracers typically have longer physical half-lives than
most PET tracers; this may partially compensate for their
disadvantages, particularly when measurements over several
hours are required to eliminate nonspeciﬁc binding and
reach equilibrium.
A major advantage of nuclear medicine imaging is the
extraordinarily high sensitivity (10−9 to 10−12 M), many
orders of magnitude greater than the sensitivities available2 Journal of Biomedicine and Biotechnology
with MRI (10−4 M). Because many molecules relevant to
neuropsychiatric disorders are present at concentrations
below 10−8 M, nuclear medicine imaging is currently the
only available in vivo method capable of quantifying subtle
cerebral pathophysiological changes that might occur before
neurostructural abnormalities take place [1].
PET and SPECT can measure biological processes, like
glucose consumption and regional cerebral blood ﬂow
(rCBF), which may change in various neuropsychiatric dis-
orders. In PET imaging, 18F-ﬂuorodeoxyglucose (18F-FDG)
is the most commonly used radiopharmaceutical. Active
neurons have higher metabolic rates and higher glucose
uptake rates than less active neurons. Similarly, active brain
regions have higher regional cerebral blood ﬂow (rCBF)
compared to less active brain regions. With PET, intravenous
15O-H2O can be administered to measure rCBF. In SPECT
imaging, 99mTc-hexamethylpropyleneamine oxime (99mTc-
HMPAO) is the most commonly used radiopharmaceutical.
Radioligands must fulﬁll several criteria for successful
PET or SPECT imaging, including stability of labeling,
suﬃcientaﬃnityandhighselectivityforthespeciﬁcreceptor,
combined with low nonspeciﬁc binding to brain tissues
that do not contain the receptor of interest, and rapid
permeation through the blood-brain barrier to permit
tracers access to receptors [2]. Selective radioligands are
available for various transmitter systems; these enable the
visualization of receptor distributions in the normal brain
and the detection of changes in receptor binding during
variousphysiologicactivitiesorunderpathologicconditions.
Quantitative imaging has gained clinical importance for
measuring theactivities ofseveralreceptors/transporters and
molecular targets, for example, quantiﬁcation of dopamine
transporters for detecting loss of functional dopaminer-
gic neuron terminals in the striatum, quantiﬁcation of
dopamine D2 receptors for studies of movement disorders
and for assessments of receptor occupancy by neuroleptic
drugs, quantiﬁcation of serotonin (5-hydroxytryptamine,
or 5-HT) receptors in aﬀective disorders, quantiﬁcation of
serotonin and norepinephrine transporters for assessment
of occupancy of antidepressants, and quantiﬁcation of β-
amyloid and acetylcholinesterase as markers of cognitive
and memory impairments. The clinical and experimental
relevance of these ﬁndings should not be underestimated.
Neuroprotective and disease-modifying drug research has
intensiﬁed, and results rely heavily on accurate, early diag-
noses.
Newadvancesinneuroimagingoﬀerthepromiseofmore
personalized treatment forindividualswith neuropsychiatric
disorders. Molecular imaging can provide patient-speciﬁc
information that allows treatment to be tailored to the
speciﬁc biological attributes of both the disease and the
patient. The eventual success of experimental therapies
rests on understanding the mechanisms of the various
neuropsychiatricdisorders,earlyandaccuratediagnoses,and
noninvasive approaches for monitoring the progression of
disease and the response to treatment.
Although nuclear imaging is a promising technique,
several barriers must be addressed to facilitate its successful
application to neuropsychiatric disorders. The major barrier
to nuclear medicine imaging of molecular targets may be
the diﬃculty in developing radiotracers. Another barrier
is the lack of current evidence to support the use of
molecular imaging as a diagnostic tool in clinical practice.
The radiotracers used as biomarkers in neuropsychiatric
disorders must have both biologic relevance and a strong
linkage to the clinical outcome of interest. Despite the
development of a large number of radioactive ligands for
receptors, most donot fulﬁll thecriteria fora goodlabel, and
only a few have been applied in clinical nuclear medicine.
Physical barriers includelimited anatomicresolutionand the
need for higher sensitivity. However, recent developments
in improved detector crystals and three-dimensional image
acquisition have markedly enhanced both sensitivity and
resolution. Radiotracer imaging with PET and, to a lesser
extent, with SPECT is ideally suited for in vivo applications,
due to its superior anatomic resolution.
2.Parkinson’s Disease andRelatedDisorders
Parkinson’s disease (PD), the second most common neu-
rodegenerative disorder, is characterized by severe loss of
nigrostriatal neurons, which results in a deﬁciency of the
neurotransmitter, dopamine [3]. Clinical diagnosis of PD
relies on the presence of characteristic motor symptoms,
including bradykinesia, rigidity, and resting tremors. In
addition, nonmotor features have been increasingly rec-
ognized as early symptoms [4, 5]. Nonetheless, an early
diﬀerentialdiagnosiscanbediﬃcult,particularlybecausethe
initial presentationmay includeoverlappingclinicalfeatures,
like essential tremor, vascular parkinsonism, drug-induced
parkinsonism, and atypical parkinsonian syndrome (i.e.,
multiplesystematrophyandprogressive supranuclearpalsy).
Often, the clinical diagnosis of PD is supported by a positive
response to dopaminergic drugs, particularly levodopa.
However, some patients with pathologically conﬁrmed PD
respond poorly to levodopa; conversely, other patients with
early multiple system atrophy or progressive supranuclear
palsy respond well to drug treatment. Previously, the rate of
misdiagnosis of idiopathic PD was as high as 24% [6, 7].
The evolution of neuroimaging techniques over the past
several years has yielded unprecedented information about
the degenerative processes in PD and other movement
disorders. PET and SPECT techniques have been successfully
employed in identifying dopaminergic dysfunction in PD by
detecting changes in brain levodopa, glucose metabolism,
and dopamine transporter binding. Several tracers can be
employed to assess the integrity of dopamine terminals
in PD. First, dopa decarboxylase activity and dopamine
turnover can both be measured with 18F-FDOPA PET. Sec-
ond, the availability of presynaptic dopamine transporters
(DATs) can be assessed with various tracers, which are
typically tropane based. Third, vesicle monoamine den-
sity in dopamine terminals can be evaluated with 11C-
dihydrotetrabenazine PET [8, 9].
The uptake of 18F-FDOPA reﬂects both the density
of the axonal terminal plexus and the activity of the
striatal aromatic amino acid decarboxylase (AADC), theJournal of Biomedicine and Biotechnology 3
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Figure 1: 99mTc-TRODAT-1 imagingon four patients with Parkinson’sdisease at diﬀerent stage andone normalcontrol.The diﬀerentiation
between normaland PD is primarily based on shape that reﬂects diﬀerences of uptake intensity.
enzyme responsible for the conversion of 18F-FDOPA to
18F-dopamine [3, 10]. Therefore, particularly in the early
stages of disease, 18F-FDOPA PET may underestimate the
degenerative process, due to the compensatory upregulation
of AADC in the remaining terminals. Moreover, because
AADCis present in the terminals of all monoaminergic neu-
rons, measurements of 18F-FDOPA uptake into extrastriatal
areas provide an index of the density of the serotonergic,
noradrenergic, and dopaminergic terminals [3, 10].
DAT is a protein complex located in presynaptic do-
paminergic nerve terminals, which serves as the primary
meansforremovingmonoaminergic neurotransmitters from
the synaptic cleft. It is therefore a potential marker of the
integrity of nigrostriatal projections. Several PET ligands
(11C-CFT, 18F-CFT, 18F-FP-CIT, and 11C-PE2I) and SPECT
tracers (123I-β-CIT, 123I-FP-CIT, 123I-altropane, 123I-PE2I,
and 99mTc-TRODAT-1) are now available to measure DAT
availability [10, 11]. The technetium-based 99mTc-TRODAT-
1 has the advantage of being relatively inexpensive and
available in kit form [12]. However, its speciﬁc signal
is lower than the 123I-based SPECT tracers. In general,
all the DAT markers have shown eﬃcacy in PD similar
to that achieved with 18F-FDOPA PET; all are able to
diﬀerentiate patients with early PD from healthy subjects
with a sensitivity and speciﬁcity of approximately 90% [13–
15]. A multicenter, phase III trial conducted at Institute
of Nuclear Energy Research (INER) indicated that patients
with PD were easily distinguished from healthy volunteers
with the 99mTc-TRODAT-1 SPECT, which had a sensitivity
of 97.2% and a speciﬁcity of 92.6% (unpublished data).
Figure 1 depicts the typical dopamine transporter images in
4 patients with PD for diﬀerent stage and a healthy control.
The diﬀerentiation between normal and Parkinson’s disease
is primarily based on shape, which reﬂects diﬀerences of
uptake intensity. The high sensitivity and speciﬁcity of DAT
images make them useful in both the clinical diagnosis of
PD and preclinical screening for asymptomatic individuals.
To date, only DaTSCAN (123I-FP-CIT) and 99mTc-TRODAT-
1 are available on the market and licensed for detecting
loss of functional dopaminergic neuron terminals in the
striatum. In contrast to 18F-FDOPA, the striatal uptake of
DAT ligands in early PD may overestimate the reduction in
terminal density due to the relative downregulation of DAT
in the remaining neurons as a response to nigral neuron
loss; this is a compensatory mechanism that acts to maintain
synaptic dopamine levels. DAT binding falls with age in
healthy subjects, but striatal 18F-FDOPA uptake does not
appear to be age dependent [3, 12, 16].
Dopaminergic neurotransmission plays an important
role in regulating several aspects of basic brain function,
including motor behavior, motivation, and working mem-
ory. Dopaminergic systems are also a central element in
the brain reward system that controls learning. There are
ﬁve subtypes of dopamine receptors, D1,D 2,D 3,D 4,
and D5.D 1 and D5 receptors are members of the D1-
like family of dopamine receptors, and D2,D 3, and D4
receptors are members of the D2-like family. The assessment
of D1-like receptors has not achieved clinical signiﬁcance;
therefore, in the past, many investigations have focused on
the D2-like receptor system. Positron-emitting ligands, like
11C-raclopride, 18F-spiperone, and 18F-methyl-benperidol
have been developed for the visualization of dopamine4 Journal of Biomedicine and Biotechnology
D2 receptors in vivo with PET; alternatively, single-proton
emitting ligands, like 123I-iodobenzamide (123I-IBZM), 123I-
epidrpride, and 123I-IBF have been developed for SPECT
imaging. 11C-raclopride, a derivative of benzamide, is cur-
rently the gold standard PET tracer for D2 receptors [17].
It is important to discriminate between idiopathic
Parkinson’s disease (IPD) and other neurodegenerative
parkinsonian syndromes (non-IPS), because there are
marked diﬀerences in the prognoses and therapies. DAT
imaging with 99mTc-TRODAT-1 SPECT has proven success-
ful in the diﬀerential diagnosis between PD and vascular
parkinsonism; patients with PD displayed a signiﬁcant
decrease in striatal 99mTc-TRODAT-1 uptake compared to
patients with vascular parkinsonism (P<. 01) [18]. Higher
diagnostic accuracy in the diﬀerential diagnosis of parkin-
sonism may be achieved by combining pre- and postsynaptic
quantitative information about the dopaminergic system.
Previous imaging studies with the most commonly used
dopamine D2 receptor tracers, 11C-raclopride and 123I-
IBZM, have consistently shown that DATs, which represent
the integrity of the nigrostriatal neurons, are downregulated
in patients with early IPD, but D2 receptors are normal or
even upregulated. In contrast, patients with multiple system
atrophy (MSA) typically show reductions in both DAT and
D2 binding [19, 20]. However, with progression of PD,
striatal D2 receptor activity returns to normal or may fall
below normal levels [2], and the small diﬀerences in D2
bindingmakeitdiﬃcultto distinguish betweenPD,IPD,and
healthy control groups (unpublished data).
Gradually, we have attained a broader understanding of
thegeneticlinkagesamongdiﬀerentaspectsofparkinsonism.
Approximately 20% of patients with PD have genetic muta-
tions [21]. Several genes, including PINK1, SNCA, parkin,
UCHL1, DJ1,a n dLRRK2, have been associated with familial
parkinsonism and/orsporadicearlyonsetParkinson’s disease
(EOPD). A 99mTc-TRODAT-1 scan showed that patients
with the PINK1 mutation displayed a rather even, symmet-
rical reduction of dopamine uptake; in contrast, patients
with late-onset Parkinson’s disease (LOPD) displayed a
dominant decline in dopamine uptake in the putamen
[22]. In addition, 99mTc-TRODAT-1 SPECT revealed that
the dopamine transporter concentration was signiﬁcantly
reduced in patients with Machado-Joseph Disease and in
asymptomatic gene carriers compared to healthy volunteers
(P<. 001). This indicated that the brain SPECT was capable
of detecting early alterations in dopamine neurons of the
striatal region [23].
Molecular imaging is also a major tool for the eval-
uation of new experimental therapeutic strategies in PD,
particularly for those that aim to restore or protect striatal
dopaminergic innervation. Neuroprotective and disease-
modifying drug research has intensiﬁed, and the results
rely heavily on accurate early diagnosis [24]. Several
teams of investigators have reported the results from
double-blind, placebo-controlled trials of human embry-
onic dopaminergic tissue transplantation for the treat-
ment of PD. Evaluations with 18F-FDOPA scans have
shown that signiﬁcant declines in the motor scores
over time after transplantation (P<. 001), based on
the Uniﬁed Parkinson Disease Rating Scale (UPDRS),
were associated with increases in putamen 18F-FDOPA
uptake at 4-year posttransplantation followups (P<. 001).
Furthermore, posttransplantation changes in putamen PET
signals and clinical outcomes were signiﬁcantly intercor-
related (P<. 02) [25, 26]. Current imaging biomarkers
may be a valuable adjunct to clinical data for assessing
both the mechanism and eﬃcacy of neuroprotective agents.
To date, functional imaging studies in these trials have
failed to demonstrate a clear-cut neuroprotective eﬀect on
nigrostriatal degeneration. In addition, discordance between
clinical and imaging outcomes has been reported in studies
that compared a dopamine agonist versus levodopa [10, 27].
Gene therapy may be potentially useful for ameliorating
the motor symptoms of PD and the motor complications of
PDtreatments.Severalgenetherapystudiesinhumansinves-
tigated transductions (with various viral vectors) of glial-
derived neurotrophic factor (GDNF), neurturin (NTN),
AADC, or glutamic acid decarboxylase (GAD) [28]. Brain
imaging with 18F-FDODA PET, 18F-FFMT, or 18F-FDG PET
was usedtoevaluateclinicaloutcomesadjuncttotheUPDRS
scores [29–33].
3.Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of
dementia. AD is characterized by progressive impairments
in cognitive function and behavior [34]. Data suggest
that the number of patients with AD worldwide will
increase from 26.6 million in 2006 to 106.8 million in
2050 [35, 36]. Beta amyloid (Aβ 1–42) is considered
a primary cause of AD, but there are numerous other
ongoing processes, including oxidative stress, inﬂammatory
reactions, microglial activation, tau phosphorylation, and
neurotransmitter impairments, that can lead to cognitive
impairments [36, 37]. Some methods have shown promise
as diagnostic tools for AD, including MRI measurements
of medial temporal lobe atrophy, PET imaging of glucose
metabolism and Aβ deposits, and cerebral spinal ﬂuid (CSF)
biomarkers. Asubstantial numberofstudieshaveshownthat
MRI measurements of hippocampal atrophy can distinguish
between subjects with AD and older subjects with normal
cognition with 80–90% accuracy [34, 38].
PETtracershavebeendevelopedforstudiesoffunctional
activity, neurotransmitter activity, and pathologic processes
in diﬀerent dementia disorders. PET imaging with 18F-FDG
has shown that AD was associated with metabolic deﬁcits
in the neocortical association areas, but normal activity was
observed in the basal ganglia, thalamus, cerebellum, primary
sensory motor cortex, and visual cortex [39]. During disease
progression, glucose metabolism continues to decline, and
this is associated with declining scores on cognitive tests
[40]. A large multicenter study showed 93% sensitivity and
speciﬁcity for distinguishing between individuals with AD
and normal individuals [34]. This indicated that 18F-FDG
PET can serve as a biomarker in clinical trials [36].
ImagingtechniquesthatincluderadiolabeledPETtracers
that can bind to aggregated Aβ peptides in Aβ plaques haveJournal of Biomedicine and Biotechnology 5
the potential of directly assessing relative brain Aβ plaque
pathology. Several research groups have applied the small-
molecule approach to the development of tracers suitable
for amyloid imaging; for example, derivatives of Congo
red, thioﬂavin, stilbene, chrysamine-G, and acridine were
developed for PET and SPECT imaging. This opens up new
possibilities for early diagnosis and provides new tools for
monitoring antiamyloid therapy in AD [36, 41–44].
18F-FDDNP was the ﬁrst PET tracer used in vivo for
detecting cerebral amyloid plaques. Increased 18F-FDDNP
binding was observed in the temporal, parietal, and frontal
regions of the AD brain, compared with brains from older
control subjects with no cognitive impairments. 18F-FDDNP
binds to both neuritic plaques and neuroﬁbrillary tangles
[45]. Pittsburgh compound B (11C-PIB), a derivative of
thioﬂavin-T, binds with high aﬃnity and high speciﬁcity
to neuritic Aβ plaques, but it shows no binding to diﬀuse
plaques or neuroﬁbrillary tangles [46]. 11C-PIB PET is
presently the most used amyloid PET ligand; it has been
studied in over 2000 subjects [39, 40]. Imaging with11C-
PIB PET showed signiﬁcantly higher retention in the frontal,
temporal, parietal, and occipital cortices and the striatum
of patients with AD compared to healthy controls (1.9-
to 1.5-fold diﬀerences). Interestingly, the increase in 11C-
PIB retention observed in mild AD patients relative to age-
matched healthy controls was larger than the decrease in 18F-
FDG uptake in AD patients relative to controls [47]. Figure 2
illustrates cerebral glucose metabolism as assessed by 18F-
FDG PET and amyloid plaque burden as assessed by 11C-PIB
PET in two AD patients and a healthy control [43].
The memory predominant subtype, amnestic mild cog-
nitive impairment (MCI), has been suggested to constitute
a transitional stage between normal aging and AD [34].
Clinical studies suggested that about 12% of patients with
the amnestic form of MCI progressed to AD within one year
a n du pt o8 0 %p r o g r e s s e dt oA Da f t e r6 y[ 48]. Glucose
metabolism is a sensitive measure ofchange in cognition and
functionalability,bothinADandinMCI;therefore,accurate
detection of changes in glucose metabolism has value in
predicting future cognitive decline [49]. Clinical follow-up
studies have shown that patients with MCI who converted to
AD showed signiﬁcantly higher 11C-PIBretention thanthose
with MCI that did not convert; this suggested the possibility
of identifying prodromal AD with β-amyloid imaging [36,
50].
To date, 11C-PIB PET is the most widely used imaging
approach for the visualization of Aβ.A l t h o u g h11C-PIB can
be used for academic studies, the 20-minute half-life of
11C and limited manufacturing access makes the molecule
unsuitable for widespread use as a routine diagnostic agent.
18F, with a half-life of 110 minutes, oﬀers much better
potential for manufacturing and distribution. In addition to
18F-FDDNP, several 18F-labeled Aβ tracers have been suc-
cessfully investigatedinclinicaltrials, including 18F-PIB(18F-
ﬂutemetamol), 18F-AV-1 (18F-BAY94-9172), and 18F-AV-45
(Florbetapir F-18). 18F-AV-45, a derivative of stilbene, has
demonstrated high binding to the Aβ aggregates in patients
with AD. In a pilot study, patients with AD and healthy
controls displayed averages of 1.67 ± 0.18 and 1.25 ±0.18,
respectively, in standard uptake value ratios (SUVRs) of 18F-
AV-45 for the cortical area relative to the cerebellum [51].
The interim results of a phase III study demonstrated that
the 18F-AV-45 PET images correlated strongly with the post-
mortem histopathology ﬁndings. The PET images correctly
identiﬁed subjects that had β-amyloid deposits and showed
where in the brain the deposits had accumulated. Recently, a
marketing application for Florbetapir was submitted to the
FDA.
In the regions of the highest retention, the speciﬁc signal
from 18F-FDDNP was only 0.3 times that of the reference
tissue; this contrasts with the 1.5–2.0-fold speciﬁc signal
with respect to the reference tissue that was associated
with the 11C-PIB [47]a n d11C-SB13 tracers [52]. Visual
assessment of 11C-PIB PET images demonstrated promise as
a supportive diagnostic marker for AD with both sensitivity
and speciﬁcity values of 0.95. Additionally, 18F-PIB showed
promise as an AD biomarker with both sensitivity and
speciﬁcity values of 0.93; in contrast, 18F-FDDNP PET
images showed only moderate accuracy, with a sensitivity of
0.81 and a speciﬁcity of 0.72 [53, 54].
Development of amyloid probes applicable to both PET
and SPECT in AD may provide a cost-eﬀective approach,
particularly when eﬀective antiamyloid therapy becomes
available. Accurate and early diagnoses of dementias will
become increasingly important as new therapies are intro-
duced. The presently available imaging ligands will be valu-
able for monitoring any reduction in Aβ plaques. Ongoing
studies with antiamyloid therapies, including a vaccination,
an Aβ ﬁbrillization inhibitor, or a secretase modulator, have
described some diﬃculties in the assessment of drug eﬀects
atautopsy.Assessments oftheeﬃcacyofantiamyloid therapy
could be greatly facilitated with the visualization of amyloid
plaques in the brains of living patients with AD [55].
One hypothesis holds that there is a cholinergic mech-
anism underlying AD; this hypothesis proposes that degen-
eration of cholinergic neurons in the basal forebrain nuclei
causes disturbances in presynaptic cholinergic terminals in
the hippocampus and neocortex, which are important for
memory disturbances and other cognitive symptoms [34].
The most important degrading enzyme for acetylcholine in
the human cortex is acetylcholinesterase, which is present
in cholinergic axons. The PET tracers, 11C-PMP and 11C-
MP4A, havebeenused to measure acetylcholinesterase activ-
ity. These tracers showed a decline in acetylcholinesterase
activity in patients with AD compared to healthy controls.
Reduction in acetylcholinesterase activity has also been
reported in patientswith MCI,particularly in thosethat later
converted to AD. This suggested that acetylcholinesterase
changes might precede the development of clinical AD
[56]. The inhibition of acetylcholinesterase with speciﬁc
therapeutic drugs, like donepezil, can also be measured with
these tracers [57].
4.AffectiveDisorders
Serotonin (5-hydroxy-tryptamine, 5-HT) is a modulatory
neurotransmitter in the human brain that regulates mood,6 Journal of Biomedicine and Biotechnology
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Figure 2:Cerebral glucosemetabolism(18F-FDG) and 11C-PIBamyloidimagingintwo AD patients andonehealthycontrol. The PETscans
show 18F-FDG and 11C-PIB at a sagittal section. MMSE: Mini Mental State Examination. Adapted from [43].
anger, reward, aggression, and appetite [58]. Serotonergic
neurotransmission is altered in many neuropsychiatric dis-
orders, including depression, anxiety disorders, biopolar
disorders(BD),compulsivedisorders,autism,schizophrenia,
AD, and PD [2, 59].
There is broad heterogeneity in the postsynaptic sero-
tonin receptors; however, the only suitable radioligands
available are for 5-HT1A and 5-HT2A receptors [2]. For
visualization of brain 5-HT1A receptor activity, the 11C-
WAY-100635 (WAY) and 18F-labeled analogs of WAY (18F-
trans-FCWAY) exhibited high aﬃnity. 5-HT1A receptors
are present in high density in the hippocampus, septum,
amygdala, hypothalamus, and neocortex of the human
brain. PET imaging with 18F-FCWAY demonstrated that
abnormalities of 5-HT1A receptors were present in aﬀective
disorders, particularly in depression and panic disorder [60–
62]. However, there were only small diﬀerences between
the study population and the healthy control groups; this
may indicate considerable overlap between groups, which
would impede a cleardiagnostic cutoﬀ.5-HT 2A receptors are
present in all neocortical regions, with lower densities in the
hippocampus,basalganglia, andthalamus. 5-HT2A receptors
have been quantiﬁed with 18F-altanserin, 18F-setoperone,
and 123I-2-ketanserin [58]. 18F-setoperone showed speciﬁc
binding in the cortex, reversibility, and a favorable ratio of
speciﬁc binding to nonspeciﬁc binding and unbound label
[63]. PET studies with 18F-Setoperone showed signiﬁcantly
decreased 5-HT2A receptor densities in neuroleptic-na¨ ıve
patientswithschizophrenia and inpatientswithAD[64,65].
The serotonin transporter (SERT, 5-HTT) plays an
important role in modulating presynaptic serotonergic func-
tion. It removes serotonin from the synaptic cleft and
terminates its function [66]. SERT is the primary target
for selective serotonin reuptake inhibitors (SSRIs), which
are commonly used for treatment of psychiatric disorders,
and as the ﬁrst-line treatment for major depression and
anxiety disorders. SERT imaging provides information on
the integrity of serotonergic neurotransmission in vivo. 123I-
β-CIT was the ﬁrst SERT marker to be applied; however,
it binds all the monoamine transporters, including SERT,
DAT, and norepinephrine transporters (NETs). The ﬁrst
PET radiotracer that was selective for brain SERT was
11C-McN5652 [67, 68]. Subsequently, two excellent PET
tracers were developed for visualization of SERT in human
brains; these are known as 11C-DASB and 11C-MADAM,
and both exhibit high aﬃnity and selectivity for SERT
[69]. Alternatively, a promising SPECT tracer was also
developed for visualization of SERT in humans; this 123I-
ADAM, a derivative of 403U76, displays high aﬃnity and
selectivity for SERT. 123I-ADAM was eﬃciently taken up in
the hypothalamus, brain stem, pons, and medial temporal
lobe [70]. Compared with previous radioligands, 11C-DASB
oﬀers both high selectivity and a favorable ratio of speciﬁc
binding relative to free and nonspeciﬁc binding. Therefore,
11C-DASB PET imaging is considered as the state-of-the-art
method for quantifying SERT in humans.
In vivo imaging studies of SERT have generally been
conducted in patients with acute depression; however, theJournal of Biomedicine and Biotechnology 7
results have been somewhat inconsistent [71]. Parsey et al.
used 11C-McN5652PETin unmedicated patients withmajor
depression.Those patientshadlowerSERTbindingpotential
in the amygdala and midbrain region compared to healthy
subjects [72]. In a study with 11C-DASB PET, brain SERT
density was investigated in subjects with a history of major
depressive episodes (MDEs). Those patients displayed no
regional diﬀerences in SERT binding potential compared to
healthy subjects [73, 74]. Newberg et al. used 123I-ADAM
SPECT and found reduced SERT binding potential in the
midbrain regions of patients with depression compared to
healthy volunteers [75]; however another study with 123I-
ADAM SPECT found no diﬀerence between similar groups
[76]. Dysfunction in serotonin neurotransmission is likely to
play a critical role in BD [77]. BD is deﬁned on the basis
of manic symptoms of varying severity. Bipolar I disorder
(BD I) is deﬁned by a full-blown episode of mania, whereas
bipolar II disorder (BD II) is deﬁned by hypomanic episodes
and depressive episodes [78]. Assessment of SERT binding
in the midbrain with 123I-ADAM SPECT demonstrated no
diﬀerences in brain SERT binding between healthy controls
and patients with BDthat were in a euthymicstate. However,
the SERT binding was lower in patients with BD I compared
to those with BD II. Furthermore, the decreased speciﬁc
uptake ratios (SURs) in BD I patients were well correlated
with the duration of the illness (R =− 0.742,P = .014)
[79]. In addition to the serotonin system, the DAT gene was
also shown to play a role in the etiology of both adult and
pediatric BD. Using 99mTc-TRODAT-1 SPECT, Chang et al.
foundthatstriatalDATavailabilitywassigniﬁcantlyhigherin
patients with euthymic BD than in healthy volunteers [80].
Aggression is one of the most extensively studied areas
of human behavior. Central serotoninergic function has
been linked to both normal and pathological aggressiveness.
Because hostility shares some similarities with aggression, it
is possible that central serotonin activity is also related to
hostility. 123I-ADAM SPECT imaging indicates that central
serotoninergic activities may play a role in hostility. The
hostile attribution subscore was negatively correlated with
SERT availability (r =− 0.71,P<. 05) [81].
Although imaging of the serotonin system has many
potential clinical uses, currently, serotonin imaging is not
used for the routine diagnosis of any neuropsychiatric
diseases. Perhaps one of the most valuable current uses
of molecular imaging technology is the determination of
the in vivo brain occupancy of a putative pharmaceutical
at the target of interest when developing a pharmaceutical
treatmentfordepression.Currently,thereisnoothermethod
available for in vivo determinations of receptor occupancy
in humans [58]. Drug concentrations in plasma may vary
by over tenfold when identical doses are administered to
diﬀerent patients. Therapeutic drug monitoring can reduce
the number of nonresponders and decrease the risk for
developing side eﬀects by identifying patients with either
insuﬃcient or excess serum concentrations of the drug
[82]. The ﬁrst SSRI occupancy study with 11C-DASB PET
found 80% striatal occupancy in multiple regions after 4
weeks of antidepressant treatment, with doses of paroxetine
and citalopram known to have clinical eﬀects distinct from
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Figure 3: (a) Eﬀect of citalopram on 11C-DASB PET scan of the
serotonin transporter in a depressed subject. Treatment was with
20mg/dayofcitalopramfor4weeks.Adapted from[73].(b)Striatal
serotonin transporter (5-HTT) occupancy in depressed subjects
after 4 weeks of treatment at minimum therapeutic doses of ﬁve
SSRIs. Adapted from [74].
placebo [73]. Thereafter, occupancy measurements of citalo-
pram, ﬂuoxetine, sertraline, paroxetine, or venlafaxine with
11C-DASB PET suggested that 80% occupancy of the SERT
was a necessary minimum for SSRI eﬃcacy for depressive
episodes. Moreover, occupancy increased as the dose or
plasma level increased, and occupancy reached a plateau at
saturating doses [74]. Figure 3(a) illustrates a typical occu-
pancy studyof citalopramon theserotonin transporters with
11C-DASB PET scan in a depressed subject [73]. Figure 3(b)
summaries thestriatal SERToccupancyindepressed subjects
after 4 weeks of treatment at minimum therapeutic doses of
ﬁve SSRIs [74]. Given the association between the clinically8 Journal of Biomedicine and Biotechnology
relevant dose and SERT occupancy for all SSRIs, it is now
generallybelievedthatan80%SERToccupancywith anSSRI
is therapeutically useful. Consequently, antidepressant drug
developmentaims for 80% serotonin transporter occupancy.
This practical approach can be applied in phase I trials
to assess whether potential new antidepressant drugs can
adequately penetrate the brain and in phase II clinical trials
to guide dosing selections [69].
NETs are responsible for the reuptake of norepinephrine
into presynaptic nerves, and they are a primary target of
antidepressants. With the development of NET tracers, like
18F-FMeNER-D2 [83]a n d11C-MRB [84], it is currently pos-
sible to investigate NET occupancy for antidepressants that
are selective norepinephrine reuptake inhibitors (SNRIs). In
an investigation with 18F-FMeNER-D2, the NET occupancy
of nortriptyline was 16% to 41%, which corresponded to a
dose of 10–75mg [83]. In addition to NET, antidepressants
also target DAT.Bupropionis thoughtto exert itsantidepres-
sive eﬀect by blocking the DAT and NET with an eﬃcacy
comparable to that of SSRIs. With bupropion treatment, the
average DAT occupancy was 20.84%, measured by 99mTc-
TRODAT-1 SPECT [85]. To achieve SNRI eﬃcacy, the
optimal and minimal occupancies of NET remain to be
determined.
For antipsychotic drugs, it was shown that the occu-
pancy of dopamine D2-like receptors was better correlated
to plasma concentrations than to the doses administered
[82]. In association with the analysis of clinical eﬀects,
Farde et al. established the concept that at least 60–70%
dopamine receptor occupancy was necessary for treating
positive symptoms of schizophrenia. However, occupancies
above 80% were associated with extrapyramidal side eﬀects
[82, 86].
5.Conclusionsand FutureDirections
With the appropriate radioligands, molecular imaging en-
ables the visualization of presynaptic and postsynaptic
sites in the dopaminergic system. This can provide crucial
information for the assessment and monitoring of neuro-
protective agents, gene therapies, and stem cell strategies
for the treatment of PD. Future studies are needed in the
developmentof new radiotracers to target nondopaminergic
brain pathways and the glial reaction to disease.
Accurate and early diﬀerentiation of dementias will
become increasingly important as new therapies are intro-
duced. Recently, reliable PET tracers for assessing the Aβ
burden in the brain have been introduced; these tracers
may be valuable for early diagnosis of the presymptomatic
stages of AD. The measurement of β-amyloid in vivo
will greatly facilitate our understanding of the underlying
pathophysiological mechanisms of AD; in addition, these
measurements will promote the testing of new antiamyloid
drugs and therapies. Although early studies were performed
with 11C-PIB, several groups have developed ﬂuorinated
compounds for widespread and routine diagnostic uses.
Although serotonin imaging has many potential clinical
applications, currently, serotonin imaging is not used for the
routine diagnosis of any neuropsychiatric diseases. Perhaps
one of the most valuable current uses of molecular imaging
technology is the determination of in vivo brain occupancy
of a putative pharmaceutical agent when developing a
treatment for depression. Finally, to achieve SNRI eﬃcacy,
the optimal and minimal occupancies of NET remain to be
determined.
In the future, the role of molecular imaging may
become more signiﬁcant in guiding therapy. Enhancements
in image resolution and speciﬁc molecular tags will permit
accurate diagnoses of a wide range of diseases, based on
both structural and molecular changes in the brain. For
widespread application, advances in molecular imaging
should include the characterization of new radiotracers,
application of modeling techniques, standardization and
automationofimage-processing techniques,andappropriate
clinical settings in large multicenter trials. The growing ﬁeld
of molecular imaging is helping nuclear medicine physicians
identify pathways into personalized patient care.
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